Biomonadic

Executive Summary

Biomonadic is a pioneering nootropics company that integrates biology and software to enable users to discover, create, and explore customized cognitive enhancement stacks. Founded in 2021 and headquartered in San Francisco, the company aims to liberate the mind through personalized, data-driven nootropic formulations. By combining biological insights with a software platform, Biomonadic empowers users to tailor their cognitive experiences, potentially disrupting the traditional supplement market. The company is privately held and operates in the RNA & Gene Therapy category, though its core offering focuses on nootropics rather than gene therapy. With a growing interest in biohacking and cognitive optimization, Biomonadic is well-positioned to capture a niche market of health-conscious individuals and professionals seeking enhanced mental performance. The company's platform likely leverages user feedback, biometric data, and ingredient science to refine its stacks. As a next-generation player, Biomonadic differentiates itself through technology integration, but it faces challenges such as regulatory uncertainties and competition from established supplement brands. Given its early stage and lack of disclosed funding or revenue, the risk profile is high. However, the convergence of biology and software in the nootropics space presents a compelling opportunity for personalized health.

Upcoming Catalysts (preview)

• Q4 2026Launch of mobile app for personalized stack creation60% success
• Q2 2026Seed funding round announcement70% success
• Q1 2027Partnership with a university for cognitive research40% success